Anti‐tumor necrosis factor (TNF) agents, such as infliximab (IFX), have been increasingly used to induce and maintain disease remission in patients with Crohn's disease (CD). Despite a considerable non‐response rate,… Click to show full abstract
Anti‐tumor necrosis factor (TNF) agents, such as infliximab (IFX), have been increasingly used to induce and maintain disease remission in patients with Crohn's disease (CD). Despite a considerable non‐response rate, little is known about the genetic predictors of response to anti‐TNF therapy in CD. Our aim in this study was to investigate the genetic factors associated with response to anti‐TNF therapy in patients with CD.
Keywords:
association trap1;
trap1 infliximab;
disease;
induced mucosal;
infliximab induced;
crohn disease
Journal Title: Journal of Gastroenterology and Hepatology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Gastroenterology and Hepatology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!